Gender-related response to fluvastatin in patients with heterozygous familial hypercholesterolaemia

Area of Science:

• Cardiology
• Pharmacology
• Genetics

Background:

• Hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitors, like fluvastatin, effectively treat heterozygous familial hypercholesterolaemia (FH).
• Previous research indicates genetic and constitutional factors influence patient response to fluvastatin.
• Gender has emerged as a key factor affecting high-density lipoprotein (HDL) cholesterol response.

Purpose of the Study:

• To investigate potential gender-specific differences in fluvastatin dosage response.
• To analyze how gender influences lipid and lipoprotein changes in FH patients treated with fluvastatin.

Main Methods:

• Retrospective analysis of fluvastatin treatment data in patients with heterozygous FH.
• Multivariate analysis to identify determinants of lipid response.
• Comparison of HDL cholesterol and LDL:HDL cholesterol ratio changes between genders across different fluvastatin doses.

Main Results:

• Significant gender-related differences in HDL cholesterol response were observed at the highest fluvastatin dose (40 mg/day), with females showing a greater increase (22.9%) than males (12.9%).
• The low-density lipoprotein (LDL) cholesterol to HDL cholesterol ratio, a marker for ischaemic heart disease risk, also showed significant gender-related differences, decreasing more in females (-38.4%) than males (-32.2%).
• No consistent gender-related differences were found for LDL cholesterol reduction.

Conclusions:

• Patient gender significantly influences the plasma lipid response to fluvastatin in heterozygous FH.
• Females generally exhibit a more pronounced positive response to fluvastatin, characterized by higher HDL cholesterol levels and a reduced LDL:HDL cholesterol ratio.
• These findings highlight the importance of considering gender in optimizing statin therapy for FH patients.